There’s a well-worn pattern in the development of AI chatbots. Researchers discover a vulnerability and exploit it to do ...
Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with FDA approval for subcutaneous use. The LIBerate Program showed sustained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback